˹

Form: 10-Q

Quarterly report pursuant to Section 13 or 15(d)

May 7, 2024

0000944809 OPKO HEALTH, INC. false --12-31 Q1 2024 0.01 0.01 1,000,000,000 1,000,000,000 726,791,854 781,936,885 29,772,753 8,655,082 0.9 195.0 2015 2016 2017 2018 2019 2020 2021 2 1,260,000 900,000 29 3.75 5 1.00 0 0 0 2 0 0 0 5 http://fasb.org/us-gaap/2024#PropertyPlantAndEquipmentNet http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent false false false false 00009448092024-01-012024-03-31 xbrli:shares 00009448092024-05-03 thunderdome:item iso4217:USD 00009448092024-03-31 00009448092023-12-31 iso4217:USDxbrli:shares 0000944809us-gaap:ServiceMember2024-01-012024-03-31 0000944809us-gaap:ServiceMember2023-01-012023-03-31 0000944809us-gaap:ProductMember2024-01-012024-03-31 0000944809us-gaap:ProductMember2023-01-012023-03-31 0000944809opk:TransferOfIntellectualPropertyAndOtherMember2024-01-012024-03-31 0000944809opk:TransferOfIntellectualPropertyAndOtherMember2023-01-012023-03-31 00009448092023-01-012023-03-31 0000944809us-gaap:CommonStockMember2023-12-31 0000944809us-gaap:TreasuryStockCommonMember2023-12-31 0000944809us-gaap:AdditionalPaidInCapitalMember2023-12-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0000944809us-gaap:RetainedEarningsMember2023-12-31 0000944809us-gaap:CommonStockMember2024-01-012024-03-31 0000944809us-gaap:TreasuryStockCommonMember2024-01-012024-03-31 0000944809us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-31 0000944809us-gaap:RetainedEarningsMember2024-01-012024-03-31 0000944809us-gaap:CommonStockMember2024-03-31 0000944809us-gaap:TreasuryStockCommonMember2024-03-31 0000944809us-gaap:AdditionalPaidInCapitalMember2024-03-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31 0000944809us-gaap:RetainedEarningsMember2024-03-31 0000944809us-gaap:CommonStockMember2022-12-31 0000944809us-gaap:TreasuryStockCommonMember2022-12-31 0000944809us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0000944809us-gaap:RetainedEarningsMember2022-12-31 00009448092022-12-31 0000944809us-gaap:CommonStockMember2023-01-012023-03-31 0000944809us-gaap:TreasuryStockCommonMember2023-01-012023-03-31 0000944809us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-31 0000944809us-gaap:RetainedEarningsMember2023-01-012023-03-31 0000944809us-gaap:CommonStockMember2023-03-31 0000944809us-gaap:TreasuryStockCommonMember2023-03-31 0000944809us-gaap:AdditionalPaidInCapitalMember2023-03-31 0000944809us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-31 0000944809us-gaap:RetainedEarningsMember2023-03-31 00009448092023-03-31 0000944809opk:LabcorpAssetPurchaseAgreementMember2024-03-282024-03-28 xbrli:pure 0000944809us-gaap:SalesRevenueNetMemberopk:CurrencyConcentrationRiskMembersrt:OtherCurrencyMember2024-01-012024-03-31 0000944809us-gaap:SalesRevenueNetMemberopk:CurrencyConcentrationRiskMembersrt:OtherCurrencyMember2023-01-012023-03-31 0000944809us-gaap:ForeignExchangeForwardMember2024-03-31 0000944809us-gaap:ForeignExchangeForwardMember2023-12-31 0000944809us-gaap:InProcessResearchAndDevelopmentMember2024-03-31 0000944809us-gaap:InProcessResearchAndDevelopmentMember2023-12-31 0000944809country:IE2024-03-31 0000944809country:IE2023-12-31 utr:Y 0000944809srt:MinimumMember2024-03-31 0000944809srt:MaximumMember2024-03-31 0000944809us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-03-31 0000944809us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2024-03-31 0000944809us-gaap:MachineryAndEquipmentMembersrt:MaximumMember2024-03-31 0000944809us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2024-03-31 0000944809us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2024-03-31 0000944809us-gaap:BuildingAndBuildingImprovementsMembersrt:MinimumMember2024-03-31 0000944809us-gaap:BuildingAndBuildingImprovementsMembersrt:MaximumMember2024-03-31 0000944809us-gaap:VehiclesMembersrt:MinimumMember2024-03-31 0000944809us-gaap:VehiclesMembersrt:MaximumMember2024-03-31 0000944809us-gaap:IsraelTaxAuthorityMember2024-01-012024-03-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberopk:MedicareAndMedicaidMember2024-01-012024-03-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberopk:MedicareAndMedicaidMember2023-01-012023-12-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberopk:IndividualPatientsMember2024-01-012024-03-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberopk:IndividualPatientsMember2023-01-012023-12-31 0000944809opk:GovernmentContractBardaMember2024-03-31 0000944809opk:GovernmentContractBardaMember2023-12-31 0000944809us-gaap:CustomerRelationshipsMember2024-03-31 0000944809us-gaap:CustomerRelationshipsMember2023-12-31 0000944809us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-31 0000944809us-gaap:TechnologyBasedIntangibleAssetsMember2023-12-31 0000944809us-gaap:TradeNamesMember2024-03-31 0000944809us-gaap:TradeNamesMember2023-12-31 0000944809us-gaap:NoncompeteAgreementsMember2024-03-31 0000944809us-gaap:NoncompeteAgreementsMember2023-12-31 0000944809us-gaap:LicensingAgreementsMember2024-03-31 0000944809us-gaap:LicensingAgreementsMember2023-12-31 0000944809opk:ProjectRegistrationMember2024-03-31 0000944809opk:ProjectRegistrationMember2023-12-31 0000944809us-gaap:OtherIntangibleAssetsMember2024-03-31 0000944809us-gaap:OtherIntangibleAssetsMember2023-12-31 0000944809us-gaap:DevelopedTechnologyRightsMembersrt:MinimumMember2024-03-31 0000944809us-gaap:DevelopedTechnologyRightsMembersrt:MaximumMember2024-03-31 0000944809us-gaap:CustomerRelationshipsMembersrt:MinimumMember2024-03-31 0000944809us-gaap:CustomerRelationshipsMembersrt:MaximumMember2024-03-31 0000944809opk:ProjectRegistrationMembersrt:MinimumMember2024-03-31 0000944809opk:ProjectRegistrationMembersrt:MaximumMember2024-03-31 0000944809us-gaap:TradeNamesMembersrt:MinimumMember2024-03-31 0000944809us-gaap:TradeNamesMembersrt:MaximumMember2024-03-31 0000944809us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2024-03-31 0000944809us-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:CurnaMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:CurnaMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:CurnaMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:RayaldeeMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:RayaldeeMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:RayaldeeMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:FinetechMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:FinetechMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:FinetechMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:ModexTherapeuticsIncMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoBiologicsMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:OpkoBiologicsMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoBiologicsMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoChileMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:OpkoChileMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoChileMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoHealthEuropeMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoMexicoMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:OpkoMexicoMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:OpkoMexicoMember2024-01-012024-03-31 0000944809opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember2023-12-31 0000944809opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember2024-03-31 0000944809opk:PharmaceuticalMemberopk:TransitionTherapeuticsMember2024-01-012024-03-31 0000944809opk:DiagnosticsMemberopk:BioreferenceMember2023-12-31 0000944809opk:DiagnosticsMemberopk:BioreferenceMember2024-03-31 0000944809opk:DiagnosticsMemberopk:BioreferenceMember2024-01-012024-03-31 0000944809opk:DiagnosticsMemberopk:OpkoDiagnosticsMember2023-12-31 0000944809opk:DiagnosticsMemberopk:OpkoDiagnosticsMember2024-03-31 0000944809opk:DiagnosticsMemberopk:OpkoDiagnosticsMember2024-01-012024-03-31 0000944809opk:PharmsynthezMember2024-03-31 0000944809opk:CocpMember2024-03-31 0000944809opk:NimsMember2024-03-31 0000944809opk:BiocardiaMember2024-03-31 0000944809opk:XeneticMember2024-03-31 0000944809opk:LeaderMedMember2024-03-31 0000944809opk:NeovascMember2024-03-31 0000944809opk:NeovascMember2023-01-012023-12-31 0000944809us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-03-31 0000944809us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-01-012024-03-31 0000944809us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-12-31 0000944809us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-01-012023-12-31 0000944809opk:GeneDxHoldingsMember2024-03-31 0000944809opk:GeneDxHoldingsMember2024-01-012024-03-31 0000944809opk:GeneDxHoldingsMember2023-01-012023-03-31 0000944809opk:VbiVaccinesIncMember2024-03-31 0000944809opk:ChromadexCorporationMember2024-03-31 0000944809opk:EloxxPharmaceuticalsIncMember2024-03-31 0000944809opk:Camp4Member2024-03-31 0000944809opk:HealthsnapIncMember2024-03-31 0000944809opk:CocpMember2023-12-31 0000944809opk:InCellDxMember2023-12-31 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMember2021-09-012021-09-30 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMember2021-09-30 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberopk:SeriesA2PreferredStockMember2024-03-31 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberopk:SeriesA2PreferredStockMember2023-12-31 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberus-gaap:RestrictedStockMember2024-03-31 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMemberus-gaap:RestrictedStockMember2023-12-31 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMember2024-03-31 0000944809us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberopk:ZebraMember2023-12-31 0000944809opk:The2029ConvertibleNotesMember2024-03-31 0000944809opk:The2029ConvertibleNotesMember2023-12-31 0000944809opk:The2025ConvertibleNotesMember2024-03-31 0000944809opk:The2025ConvertibleNotesMember2023-12-31 0000944809opk:The2033SeniorNotesMember2024-03-31 0000944809opk:The2033SeniorNotesMember2023-12-31 0000944809opk:The2023ConvertibleNotesMember2024-03-31 0000944809opk:The2023ConvertibleNotesMember2023-12-31 0000944809opk:JPMorganChaseMember2024-03-31 0000944809opk:JPMorganChaseMember2023-12-31 0000944809opk:ChileanAndSpanishLinesOfCreditMember2024-03-31 0000944809opk:ChileanAndSpanishLinesOfCreditMember2023-12-31 0000944809opk:ConvertibleNotesMember2024-03-31 0000944809opk:ConvertibleNotesMember2023-12-31 0000944809opk:LineOfCreditAndNotesAndLoansPayableCurrentMember2024-03-31 0000944809opk:LineOfCreditAndNotesAndLoansPayableCurrentMember2023-12-31 0000944809us-gaap:OtherNoncurrentLiabilitiesMember2024-03-31 0000944809us-gaap:OtherNoncurrentLiabilitiesMember2023-12-31 0000944809opk:The2029ConvertibleNotesMember2024-01-09 0000944809opk:The2029Convertible144ANotesMember2024-01-09 0000944809opk:The2029ConvertibleNotesMember2024-01-092024-01-09 00009448092024-01-092024-01-09 0000944809opk:The2029ConvertibleAffiliateNotesMember2024-01-09 0000944809opk:The2023ConvertibleNotesMember2024-01-09 0000944809opk:The2029ConvertibleNotesMember2024-01-092024-03-28 0000944809opk:The2029ConvertibleNotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMember2024-01-092024-01-09 0000944809opk:The2029ConvertibleNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-01-092024-01-09 0000944809opk:The2029ConvertibleNotesMemberopk:ScenarioEventofDefaultMember2024-01-092024-01-09 0000944809opk:The2029Convertible144ANotesMember2023-12-31 0000944809opk:The2029Convertible144ANotesMember2024-03-31 0000944809opk:The2029Convertible144ANotesMember2024-01-012024-03-31 0000944809opk:The2025NotesMemberus-gaap:ConvertibleDebtMemberopk:ScenarioEventofDefaultMember2019-02-28 0000944809opk:ConversionOfThe2025NotesIntoCommonStockMember2021-05-012021-05-31 0000944809opk:The2025NotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:The2029ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2024-01-092024-01-09 0000944809opk:The2025NotesMemberus-gaap:DebtInstrumentRedemptionPeriodOneMemberus-gaap:ConvertibleDebtMember2019-02-012019-02-01 0000944809opk:The2025NotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMemberus-gaap:ConvertibleDebtMember2019-02-012019-02-01 0000944809opk:The2025NotesMemberus-gaap:ConvertibleDebtMember2024-01-22 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2018-02-28 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2018-02-012018-02-28 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2023-02-102023-02-10 0000944809opk:The2029ConvertibleAffiliateNotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember2023-01-31 0000944809opk:The2033SeniorNotesMemberus-gaap:SeniorNotesMember2013-01-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2013-02-012016-12-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2019-02-01 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2024-01-012024-03-31 0000944809opk:The2033SeniorNotesMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:BridgeLoanMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:LetterOfCreditMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2015-11-30 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2023-06-29 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMemberopk:QuarterlyAvailabilityIs50OrMoreMemberopk:SecuredOvernightFinancingRate12MonthsMember2024-01-012024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMemberopk:QuarterlyAvailabilityIs50OrMoreMember2024-01-012024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2024-01-012024-03-31 0000944809us-gaap:RevolvingCreditFacilityMemberopk:CreditAgreementMemberus-gaap:LineOfCreditMember2023-12-31 0000944809opk:BioreferenceMember2024-03-31 0000944809opk:JPMorganChaseMember2024-03-31 0000944809opk:JPMorganChaseMember2023-12-31 0000944809opk:ItauBankMember2024-03-31 0000944809opk:ItauBankMember2023-12-31 0000944809opk:BankOfChileMember2024-03-31 0000944809opk:BankOfChileMember2023-12-31 0000944809opk:BiceBankMember2024-03-31 0000944809opk:BiceBankMember2023-12-31 0000944809opk:ScotiabankMember2024-03-31 0000944809opk:ScotiabankMember2023-12-31 0000944809opk:SantanderBankMember2024-03-31 0000944809opk:SantanderBankMember2023-12-31 0000944809opk:SecurityBankMember2024-03-31 0000944809opk:SecurityBankMember2023-12-31 0000944809opk:EstadoBankMember2024-03-31 0000944809opk:EstadoBankMember2023-12-31 0000944809opk:BciBankMember2024-03-31 0000944809opk:BciBankMember2023-12-31 0000944809opk:InternacionalBankMember2024-03-31 0000944809opk:InternacionalBankMember2023-12-31 0000944809opk:ConsorcioBankMember2024-03-31 0000944809opk:ConsorcioBankMember2023-12-31 0000944809opk:BancoDeSabadellMember2024-03-31 0000944809opk:BancoDeSabadellMember2023-12-31 0000944809opk:SantanderBank2Member2024-03-31 0000944809opk:SantanderBank2Member2023-12-31 0000944809us-gaap:LineOfCreditMember2024-03-31 0000944809us-gaap:LineOfCreditMember2023-12-31 0000944809opk:NotesPayableAndOtherLongTermLiabilitiesMember2024-03-31 0000944809opk:NotesPayableAndOtherLongTermLiabilitiesMember2023-12-31 0000944809opk:NotesAndOtherDebtMember2024-03-31 0000944809opk:NotesAndOtherDebtMember2023-12-31 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2023-12-31 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-31 0000944809us-gaap:AccumulatedTranslationAdjustmentMember2024-03-31 0000944809us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-31 0000944809us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-31 0000944809us-gaap:FairValueMeasurementsRecurringMember2024-03-31 0000944809us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809us-gaap:FairValueMeasurementsRecurringMember2023-12-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2025ConvertibleNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2025ConvertibleNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809opk:The2025ConvertibleNotesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ConvertibleDebtMember2024-03-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2023-12-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-01-012024-03-31 0000944809us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2023-12-31 0000944809opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2024-03-31 0000944809opk:InvestmentNetMemberopk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2023-12-31 0000944809opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-03-31 0000944809opk:AccruedExpensesMemberus-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-12-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2024-01-012024-03-31 0000944809opk:The2029ConvertibleNotesMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:NondesignatedMember2023-01-012023-03-31 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2024-01-012024-03-31 0000944809opk:CommonStockOptionsWarrantsMemberus-gaap:NondesignatedMember2023-01-012023-03-31 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2024-01-012024-03-31 0000944809us-gaap:ForeignExchangeForwardMemberus-gaap:NondesignatedMember2023-01-012023-03-31 0000944809us-gaap:NondesignatedMember2024-01-012024-03-31 0000944809us-gaap:NondesignatedMember2023-01-012023-03-31 0000944809opk:The2023ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2024-01-09 0000944809opk:RuenhuiBiopharmaceuticalsIncMember2023-05-04 0000944809opk:LicenseAgreementMemberopk:RuenhuiBiopharmaceuticalsIncMember2023-05-042023-05-04 0000944809opk:LicenseAgreementMemberopk:RuenhuiBiopharmaceuticalsIncMember2023-05-04 0000944809opk:TransitionServicesAgreementMemberopk:GeneDxMember2024-01-012024-03-31 0000944809opk:ServicesRenderedMemberopk:TransitionServicesAgreementMemberopk:GeneDxMember2024-01-012024-03-31 0000944809opk:TransitionServicesAgreementMemberopk:GeneDxMember2024-03-31 0000944809srt:DirectorMemberopk:PharmsynthezMember2024-03-31 0000944809opk:ZebraMember2024-03-31 0000944809opk:NeovascMember2023-10-012023-12-31 0000944809opk:GeneDxMember2024-03-31 utr:sqft 00009448092019-08-01 0000944809opk:BeckmanCoulterMember2024-01-012024-03-31 0000944809opk:IntegratedDNATechnologiesIncMember2024-01-012024-03-31 0000944809opk:LeicaMicrosystemsIncMember2024-01-012024-03-31 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2024-01-012024-03-31 0000944809opk:ReimbursementOfTravelExpensesMembersrt:ExecutiveOfficerMember2023-01-012023-03-31 0000944809us-gaap:ForeignCountryMemberus-gaap:IsraelTaxAuthorityMemberopk:TaxYear2014ThroughTaxYear2020Member2022-12-292022-12-29 0000944809us-gaap:SettledLitigationMember2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMember2022-07-14 0000944809us-gaap:SettledLitigationMembercountry:US2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMemberopk:CommonwealthMember2022-07-142022-07-14 0000944809us-gaap:SettledLitigationMemberstpr:CT2022-07-142022-07-14 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2024-01-012024-03-31 0000944809opk:HealthcareInsurersMemberus-gaap:ServiceMember2023-01-012023-03-31 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2024-01-012024-03-31 0000944809opk:GovernmentPayersMemberus-gaap:ServiceMember2023-01-012023-03-31 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2024-01-012024-03-31 0000944809opk:ClientPayersMemberus-gaap:ServiceMember2023-01-012023-03-31 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2024-01-012024-03-31 0000944809us-gaap:SelfPayMemberus-gaap:ServiceMember2023-01-012023-03-31 0000944809opk:RayaldeeMember2024-01-012024-03-31 0000944809opk:RayaldeeMember2023-01-012023-03-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-12-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-12-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-12-31 0000944809opk:RayaldeeMember2023-12-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-01-012024-03-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-01-012024-03-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-01-012024-03-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2024-03-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2024-03-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2024-03-31 0000944809opk:RayaldeeMember2024-03-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2022-12-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2022-12-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2022-12-31 0000944809opk:RayaldeeMember2022-12-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-01-012023-03-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-01-012023-03-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-01-012023-03-31 0000944809opk:RayaldeeMemberopk:ChargebacksDiscountsRebatesAndFeesMember2023-03-31 0000944809opk:RayaldeeMemberopk:GovernmentalMember2023-03-31 0000944809opk:RayaldeeMemberopk:SalesReturnsMember2023-03-31 0000944809opk:RayaldeeMember2023-03-31 0000944809opk:MerckSharpDohmeLLCMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:MerckAgreementMember2023-01-012023-12-31 0000944809opk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:NicoyaMacauLimitedMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:TransferOfIntellectualPropertyAndOtherMemberopk:RoyaltyAgreementMember2024-01-012024-03-31 0000944809opk:TransferOfIntellectualPropertyAndOtherMemberopk:RoyaltyAgreementMember2023-01-012023-03-31 0000944809opk:BardaAgreementMember2024-01-012024-03-31 0000944809opk:BardaAgreementMember2023-09-282023-09-28 0000944809opk:BardaAgreementMember2023-09-28 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-082023-03-08 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-08 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-12-31 0000944809opk:MerckSharpDohmeLLCMemberopk:MerckAgreementMember2023-03-092024-03-31 0000944809opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-14 0000944809opk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-142021-09-14 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-142021-09-14 0000944809opk:LeaderMedMemberopk:LeaderMedJointVentureMemberus-gaap:CorporateJointVentureMember2021-09-14 0000944809opk:Camp4Member2021-07-062021-07-06 0000944809opk:Camp4Member2021-07-06 0000944809opk:Camp4Memberopk:DravetSyndromeProductsMember2021-07-06 0000944809opk:Camp4Memberopk:NondravetSyndromeProductsMember2021-07-06 0000944809opk:Camp4Memberopk:DravetSyndromeProductsMember2021-07-062021-07-06 0000944809opk:Camp4Memberopk:NondravetSyndromeProductsMember2021-07-062021-07-06 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2021-06-182021-06-18 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2021-06-18 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2023-03-31 0000944809opk:EirgenMemberopk:NicoyaMacauLimitedMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-03-31 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember2023-01-012023-12-31 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:TransferOfIntellectualPropertyAndOtherMember2022-01-012022-12-31 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:FirstMarketingApprovalOfRayaldeeInEuropeMemberopk:DevelopmentAndLicenseAgreementMember2020-05-052020-05-05 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:GermanyPriceApprovalByLocalSickFundAssociationMemberopk:DevelopmentAndLicenseAgreementMember2020-05-052020-05-05 0000944809opk:EirgenMemberopk:ViforFreseniusMedicalCareRenalPharmaLtdMemberopk:DevelopmentAndLicenseAgreementMember2020-05-05 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-01-012023-12-31 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2022-01-012022-12-31 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2024-03-31 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-12-31 0000944809opk:PfizerIncMembersrt:MinimumMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMembersrt:MaximumMemberopk:PfizerAgreementMember2019-10-01 0000944809opk:PfizerIncMemberopk:PfizerAgreementMember2023-07-012024-03-31 0000944809us-gaap:IntersegmentEliminationMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:PharmaceuticalMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberopk:DiagnosticsMember2023-01-012023-03-31 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2024-01-012024-03-31 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:PharmaceuticalMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberus-gaap:ProductMemberopk:DiagnosticsMember2023-01-012023-03-31 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2024-01-012024-03-31 0000944809us-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:PharmaceuticalMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:TransferOfIntellectualPropertyAndOtherMemberopk:DiagnosticsMember2023-01-012023-03-31 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2024-01-012024-03-31 0000944809us-gaap:CorporateNonSegmentMemberopk:TransferOfIntellectualPropertyAndOtherMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2024-01-012024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2023-01-012023-03-31 0000944809us-gaap:CorporateNonSegmentMember2024-01-012024-03-31 0000944809us-gaap:CorporateNonSegmentMember2023-01-012023-03-31 0000944809country:US2024-01-012024-03-31 0000944809country:US2023-01-012023-03-31 0000944809country:IE2024-01-012024-03-31 0000944809country:IE2023-01-012023-03-31 0000944809country:CL2024-01-012024-03-31 0000944809country:CL2023-01-012023-03-31 0000944809country:ES2024-01-012024-03-31 0000944809country:ES2023-01-012023-03-31 0000944809country:IL2024-01-012024-03-31 0000944809country:IL2023-01-012023-03-31 0000944809country:MX2024-01-012024-03-31 0000944809country:MX2023-01-012023-03-31 0000944809opk:OtherCountriesMember2024-01-012024-03-31 0000944809opk:OtherCountriesMember2023-01-012023-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:PharmaceuticalMember2023-12-31 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2024-03-31 0000944809us-gaap:OperatingSegmentsMemberopk:DiagnosticsMember2023-12-31 0000944809us-gaap:CorporateNonSegmentMember2024-03-31 0000944809us-gaap:CorporateNonSegmentMember2023-12-31 0000944809us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-31 0000944809us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-03-31 0000944809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-03-31 0000944809opk:OfficeSpaceMemberopk:ModexTherapeuticsIncMember2023-01-02 utr:acre 0000944809opk:OfficeSpaceMemberopk:ModexTherapeuticsIncMember2023-01-022023-01-02

Table of Contents



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549


FORM 10-Q


(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number 001-33528


˹.

(Exact Name of Registrant as Specified in Its Charter)


Delaware

75-2402409

(State or Other Jurisdiction of
Incorporation or Organization)

(I.R.S. Employer
Identification No.)

4400 Biscayne Blvd.

Miami FL 33137

(Address of Principal Executive Offices) (Zip Code)

(305) 575-4100

(Registrants Telephone Number, Including Area Code)


Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.01 per share

OPK

NASDAQ Global Select Market

Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90days.☒Yes☐No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Yes☐No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act:

Large accelerated filer

x

Acceleratedfiler

Non-accelerated filer

Smallerreportingcompany

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act):Yes☒No

As of May 3, 2024, the registrant had 696,991,677 shares of Common Stock outstanding.



TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item1.

Financial Statements

Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 (unaudited)

6

Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 (unaudited)

7

Condensed Consolidated Statements of Comprehensive lossfor the three months ended March 31, 2024 and 2023 (unaudited)

8

Condensed Consolidated Statements of Equityfor the three months ended March 31, 2024 and 2023 (unaudited)

9

Condensed Consolidated Statements of Cash Flowsfor the three months ended March 31, 2024 and 2023 (unaudited)

11

Notes to Condensed Consolidated Financial Statements (unaudited)

12

Item2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

46

Item3.

Quantitative and Qualitative Disclosures About Market Risk

56

Item4.

Controls and Procedures

57

PART II. OTHER INFORMATION

Item1.

Legal Proceedings

58

Item1A.

Risk Factors

58

Item2.

Unregistered Sales of Equity Securities and Use of Proceeds

58

Item3.

Defaults Upon Senior Securities

58

Item4.

Mine Safety Disclosures

59

Item5.

Other Information

59

Item6.

Exhibits

59

Signatures

60

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (“PSLRA”), Section27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements about our expectations, beliefs or intentions regarding our product development efforts, business, financial condition, results of operations, strategies or prospects, operating results, cash flows and/or financial condition. You can identify forward-looking statements by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described below and in “Item 1A-Risk Factors” of our Annual Report on Form 10-K for the year ended December31, 2023, and described from time to time in our other filings with the Securities and Exchange Commission (the “SEC”). We do not undertake any obligation to update forward-looking statements, except to the extent required by applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance.

Risks and uncertainties, the occurrence of which could adversely affect our business, include the following:

we have had a history of losses and may not generate sustained positive cash flow sufficient to fund our operations and research and development programs;

our need for, and ability to obtain, additional financing when needed on favorable terms, or at all;

adverse results in material litigation matters or governmental inquiries;

the risks inherent in developing, obtaining regulatory approvals for and commercializing new, commercially viable and competitive products and treatments;

our research and development activities may not result in commercially viable products;

that earlier clinical results of effectiveness and safety may not be reproducible or indicative of future results;

that we may fail tosuccessfully commercialize Somatrogon (hGH-CTP);

that we may not generate or sustain profits or cash flow from our laboratory operations or substantial revenue from NGENLA (Somatrogon (hGH-CTP)),Rayaldee and our other pharmaceutical and diagnostic products;

our ability to manage our growth and our expanded operations;

that our acquisition of ModeX Therapeutics, Inc. will be successful and the products in the R&D pipeline will ultimately be commercialized;

that currently available over-the-counter and prescription products, as well as products under development by others, may prove to be as or more effective than our products for the indications being studied;

our ability and our distribution and marketing partners’ ability to comply with regulatory requirements regarding the sales, marketing and manufacturing of our products and product candidates and the operation of our laboratories;

the performance of our third-party distribution partners, licensees and manufacturers over which we have limited control;

changes in regulation and policies in the U.S. and other countries, including increasing downward pressure on healthcare reimbursement;

increased competition, including price competition;

our success is dependent on the involvement and continued efforts of our Chairman and Chief Executive Officer;

integration challenges for acquired businesses;

changing relationships with payors, including the various state and multi-state programs, suppliers and strategic partners;

efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;

our ability to maintain reimbursement coverage for our products and services, including Rayaldee and the 4Kscore test;

failure to timely or accurately bill and collect for our services;

the information technology systems that we rely on may be subject to unauthorized tampering, cyberattack or other data security or privacy incidents that could impact our billing processes or disrupt our operations;

failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;

failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services;

failure to maintain the security of patient-related information;

our ability to obtain and maintain intellectual property protection for our products;

our ability to defend our intellectual property rights with respect to our products;

our ability to operate our business without infringing the intellectual property rights of others;

our ability to attract and retain key scientific and management personnel;

the risk that the carrying value of certain assets may exceed the fair value of the assets causing us to impair goodwill or other intangible assets;

our ability to comply with the terms of our 2022 Corporate Integrity Agreement with the U.S. Office of Inspector General of the Department of Health and Human Services;

failure to obtain and maintain regulatory approval outside the U.S.;

legal, economic, political, regulatory, currency exchange, and other risks associated with international operations; and

disruptions to operations, including impact on employees, and business continuity, including physical damage or impaired access to company facilities, office of technology from the current conflict in Israel and the Gaza Strip

PART I. FINANCIAL INFORMATION

Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the “Company”, “OPKO”, “we”, “our”, “ours”, and “us” refer to ˹., a Delaware corporation, including our consolidated subsidiaries.

Item 1. Financial Statements

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

˹. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEET

(Unaudited)

(In thousands, except share and per share data)

March 31, 2024

December 31, 2023

ASSETS

Current assets:

Cash and cash equivalents

$ 75,639 $ 95,881

Accounts receivable, net

111,367 123,379

Inventory, net

59,366 65,697

Other current assets and prepaid expenses

24,652 24,519

Assets held for sale

120,279

Total current assets

391,303 309,476

Property, plant and equipment, net

64,165 75,429

Intangible assets, net

680,034 740,283

In-process research and development

195,000 195,000

Goodwill

530,615 598,260

Investments

40,990 16,082

Operating lease right-of-use assets

63,331 68,088

Other assets

8,578 9,080

Total assets

$ 1,974,016 $ 2,011,698

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable

$ 71,157 $ 69,677

Accrued expenses

88,772 90,086

Current maturities of operating leases

11,742 12,996

Current portion of convertible notes

170

Current portion of lines of credit and notes payable

22,820 27,293

Liabilities associated with assets held for sale

9,677

Total current liabilities

204,338 200,052

Operating lease liabilities

50,931 54,140

Long term portion of convertible notes

323,108 214,325

Deferred tax liabilities

121,635 126,773

Other long-term liabilities, principally contract liabilities, contingent consideration and lines of credit

21,196 27,189

Total long-term liabilities

516,870 422,427

Total liabilities

721,208 622,479

Equity:

Common Stock - $0.01 par value, 1,000,000,000 shares authorized; 726,791,854 and 781,936,885 shares issued at March 31, 2024 and December 31, 2023, respectively

7,269 7,820

Treasury Stock - 29,772,753, and 8,655,082 shares at March 31, 2024 and December 31, 2023, respectively

(1,791 ) (1,791 )

Additional paid-in capital

3,386,147 3,433,006

Accumulated other comprehensive loss

(45,195 ) (38,030 )

Accumulated deficit

(2,093,622 ) (2,011,786 )

Total shareholders’ equity

1,252,808 1,389,219

Total liabilities and equity

$ 1,974,016 $ 2,011,698

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

˹. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except share and per share data)

For the three months ended March 31,

2024

2023

Revenues:

Revenue from services

$ 126,890 $ 132,368

Revenue from products

38,047 40,383

Revenue from transfer of intellectual property and other

8,749 64,826

Total revenues

173,686 237,577

Costs and expenses:

Cost of service revenue

109,873 114,059

Cost of product revenue

21,744 24,255

Selling, general and administrative

70,167 75,642

Research and development

21,937 32,605

Contingent consideration

136

Amortization of intangible assets

21,437 21,474

Total costs and expenses

245,158 268,171

Operating loss

(71,472 ) (30,594 )

Other income and (expense), net:

Interest income

813 1,030

Interest expense

(7,686 ) (3,391 )

Fair value changes of derivative instruments, net

(26,161 ) (1,059 )

Other income, net

21,323 17,017

Other income (expense), net

(11,711 ) 13,597

Loss before income taxes and investment losses

(83,183 ) (16,997 )

Income tax benefit (provision)

1,350 (1,233 )

Net loss before investment losses

(81,833 ) (18,230 )

Loss from investments in investees

(3 ) (37 )

Net loss

$ (81,836 ) $ (18,267 )

Loss per share, basic and diluted:

Loss per share

$ (0.12 ) $ (0.02 )

Weighted average common shares outstanding, basic and diluted

706,882,189 751,506,257

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

˹. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(In thousands)

For the three months ended March 31,

2024

2023

Net loss

$ (81,836 ) $ (18,267 )

Other comprehensive income (loss), net of tax:

Change in foreign currency translation and other comprehensive income (loss)

(7,166 ) 5,712

Comprehensive loss

$ (89,002 ) $ (12,555 )

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

(In thousands, except share data)

For the three months ended March 31, 2024

Accumulated

Additional

Other

Common Stock

Treasury

Paid-In

Comprehensive

Accumulated

Shares

Dollars

Shares

Dollars

Capital

Loss

Deficit

Total

Balance at December 31, 2023

781,936,885 $ 7,820 (8,655,082 ) $ (1,791 ) $ 3,433,006 $ (38,030 ) $ (2,011,786 ) $ 1,389,219

Equity-based compensation expense

Exercise of common stock options and warrants

2,590 2,590

2025 convertible notes

(21,117,671 )

Share Repurchase

(55,145,031 ) (551 ) (49,449 ) (50,000 )

Net loss

(81,836 ) (81,836 )

Other comprehensive loss

(7,165 ) (7,165 )

Balance at March 31, 2024

726,791,854 $ 7,269 (29,772,753 ) $ (1,791 ) $ 3,386,147 $ (45,195 ) $ (2,093,622 ) $ 1,252,808

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

CONSOLIDATED STATEMENTS OF EQUITY

(Unaudited)

(In thousands, except share data)

For the three months ended March 31, 2023

Accumulated

Additional

Other

Common Stock

Treasury

Paid-In

Comprehensive

Accumulated

Shares

Dollars

Shares

Dollars

Capital

Loss

Deficit

Total

Balance at December 31, 2022

781,306,164 $ 7,813 (8,655,082 ) $ (1,791 ) $ 3,421,872 $ (43,323 ) $ (1,822,923 ) $ 1,561,648

Equity-based compensation expense

2,717 2,717

Net loss

(18,267 ) (18,267 )

Other comprehensive income

5,712 5,712

Balance at March 31, 2023

781,306,164 $ 7,813 (8,655,082 ) $ (1,791 ) $ 3,424,589 $ (37,611 ) $ (1,841,190 ) $ 1,551,810

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

˹. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

For the three months ended March 31,

2024

2023

Cash flows from operating activities:

Net loss

$ (81,836 ) $ (18,267 )

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

25,820 26,446

Non-cash interest

3,843 678

Amortization of deferred financing costs

519 296

Losses from investments in investees

3 37

Equity-based compensation – employees and non-employees

2,590 2,717

Realized loss (gain) on disposal of fixed assets and sales of equity securities

(47 ) 1,845

Change in fair value of equity securities and derivative instruments

1,251 (7,130 )

Loss on conversion convertible senior notes

757

Change in fair value of contingent consideration

136

Deferred income tax (benefit) provision

(2,680 ) 102

Changes in assets and liabilities:

Accounts receivable, net

9,518 7,364

Inventory, net

2,274 1,306

Other current assets and prepaid expenses

(552 ) (58,902 )

Other assets

7 772

Accounts payable

2,789 12,759

Foreign currency measurement

1,225 (2,355 )

Contract liabilities

2

Accrued expenses and other liabilities

(1,047 ) 9,547

Net cash used in operating activities

(35,566 ) (22,647 )

Cash flows from investing activities:

Investments in investees

(5,000 )

Proceeds from the sale of property, plant and equipment

48 320

Capital expenditures

(4,443 ) (3,037 )

Net cash used in investing activities

(4,395 ) (7,717 )

Cash flows from financing activities:

Issuance of 3.00% convertible senior notes, net (including related parties)

230,000

Debt issuance costs

(8,562 )

Share repurchase

(50,000 )

Borrowings on lines of credit

163,703 165,288

Repayments of lines of credit

(168,241 ) (175,407 )

Redemption of 2025 Notes and 2033 Senior Notes

(146,287 ) (3,000 )

Net cash provided by (used in) financing activities

20,613 (13,119 )

Effect of exchange rate changes on cash and cash equivalents

(894 ) 1,122

Net decrease in cash and cash equivalents

(20,242 ) (42,361 )

Cash and cash equivalents at beginning of period

95,881 153,191

Cash and cash equivalents at end of period

$ 75,639 $ 110,830

SUPPLEMENTAL INFORMATION:

Interest paid

$ 3,125 $ 3,830

Income taxes paid, net of refunds

$ 1,063 $ 477

Assets acquired by finance leases

$ $ 960

The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.

˹. and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

NOTE 1 BUSINESS AND ORGANIZATION

OPKOHealth,Inc.,aDelawarecorporation(“OPKO”,the “Company”, “we”, “us”,or “our”)is a diversified healthcare company that seeks to establish industry leading positions in large and rapidly growing markets. Our pharmaceutical business features Rayaldee, a U.S. Food and Drug Administration (“FDA”) approved treatment for secondary hyperparathyroidism (“SHPT”) in adults with stage 3 or 4 chronic kidney disease (“CKD”) and vitamin D insufficiency, and Somatrogon (hGH-CTP), a once-weekly human growth hormone injection. We have partnered with Pfizer Inc. (“Pfizer”) for the development and commercialization of Somatrogon (hGH-CTP). Regulatory approvals for Somatrogon (hGH-CTP) for the treatment of growth hormone deficiency in children and adolescents have been secured in over 50 markets, including the United States, European Union (“EU”) Member States, Japan, Canada, and Australia, where it is marketed under the brand name NGENLA®. Through our 2022 acquisition of ModeX Therapeutics, Inc. (“ModeX”), we haveexpanded our pharmaceutical pipeline with early-stage immune therapies targeting cancer and infectious diseases.

Our diagnostics business, BioReference Health, LLC (“BioReference”), is one of the nation’s largest full-service laboratories, with a sales and marketing team focused on growth and new product integration, including the 4Kscore prostate cancer test. BioReference primarily serves customers in major metropolitan areas across the United States. We offer a comprehensive clinical diagnostics menu, including hematology, clinical chemistry, immunoassays, infectious disease testing, serology, hormone analyses, toxicology assays, Pap smears, anatomic pathology, and COVID-19 testing. Our laboratory services are marketed directly to physicians, geneticists, hospitals, clinics, correctional facilities, and other healthcare providers.

The Company maintains established, revenue-generating pharmaceutical platforms in Spain, Ireland, Chile, and Mexico, contributing to positive cash flow and facilitating market entry for our development pipeline. In addition to these platforms, we operate a global pharmaceutical development and commercial supply company, a global supply chain operation, and manufacture specialty active pharmaceutical ingredients (API) in Israel through our subsidiary, FineTech, which we expect will facilitate the development of our pipeline of molecules and compounds for our proprietary molecular diagnostic and therapeutic products.

Our management team possesses extensive industry experience in development, regulatory affairs, and commercialization. Their industry relationships support the identification and pursuit of commercial opportunities. Research and development activities are primarily conducted in facilities located in Weston, Massachusetts, Waterford, Ireland, Kiryat Gat, Israel, and Barcelona, Spain.

On March 27, 2024, we and Laboratory Corporation of America Holdings (“Labcorp”) entered into a definitive agreement (the “Labcorp Asset Purchase Agreement”), pursuant to which Labcorp agreed to acquire select assets of BioReference (the “BioReference Transaction”). The purchase price for the Bio Reference Transaction is $237.5 million. The assets contemplated by the BioReference Transaction include BioReference's laboratory testing businesses focused on clinical diagnostics, reproductive health, and women's health across the United States, excluding New York and New Jersey operations. These assets include patient service centers, specific customer contracts, and operating assets. The Purchase Agreement contains customary representations, warranties, covenants and indemnification provisions for a transaction of this size and type, including, among other things, customary covenants relating to (i) the conduct of the Business between the signing of the Purchase Agreement and the closing of the Transaction and (ii) the efforts of the parties to cause the Transaction to be consummated, including obtaining certain consents and approvals. The consummation of the BioReference Transaction is subject to the satisfaction or waiver of customary closing conditions, including the expiration or termination of any required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The Company anticipates closing the BioReference Transaction in the second half of 2024.

As of March 31, 2024, the Labcorp Asset Purchase Agreement met the held-for-sale accounting criteria. Accordingly, the related assets and liabilities are classified as held for sale in our consolidated balance sheet. As of March 31, 2024, the select assets to be purchased in the BioReference Transaction are included in our diagnostics segment.

NOTE 2 FOREIGN EXCHANGE RATES

Foreign Currency Exchange Rates

Approximately 21.5% of our revenue for the three months ended March 31, 2024, was denominated in currencies other than the U.S. Dollar (USD). This compares to 18.5% for the same period in 2023. Our financial statements are reported in USD; therefore, fluctuations in exchange rates affect the translation of foreign-denominated revenue and expenses. During the first quarter of 2024 and the year ended December 31, 2023, our most significant currency exchange rate exposures were to the Euro and the Chilean Peso. Gross accumulated currency translation adjustments, recorded as a separate component of shareholders’ equity, totaled $41.8 million and $34.6 million at March 31, 2024 and December 31, 2023, respectively.

12

We are subject to foreign currency transaction risk due to fluctuations in exchange rates between the time a transaction is initiated and settled. To mitigate this risk, we use foreign currency forward contracts. These contracts fix an exchange rate, allowing us to offset potential losses (or gains) caused by exchange rate changes at the settlement date. As of March 31, 2024, we held no open foreign exchange forward contracts related to inventory purchases on letters of credit. As of December 31, 2023, we held 52 open foreign exchange forward contracts related to inventory purchases on letters of credit. These contracts matured monthly through January 2024 with a total notional value of approximately $2.9 million.

NOTE 3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation. The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of only normal recurring adjustments or adjustments otherwise disclosed herein) considered necessary to present fairly the Company’s results of operations, financial position and cash flows have been made. The results of operations and cash flows for the three months ended March 31, 2024 are not necessarily indicative of the results of operations and cash flows that may be reported for the remainder of 2024 or any other future periods. The unaudited Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2023.

Principles of consolidation. The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of ˹. and our wholly-owned subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.

Use of estimates. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.

Cash and cash equivalents. Cash and cash equivalents include short-term, interest-bearing instruments with original maturities of 90 days or less at the date of purchase. We also consider all highly liquid investments with original maturities at the date of purchase of 90 days or less as cash equivalents. These investments include money markets, bank deposits, certificates of deposit and U.S. treasury securities.

Inventories. Inventories are valued at the lower of cost and net realizable value. Cost is determined by the first-in, first-out method. We consider such factors as the amount of inventory on hand, estimated time required to sell such inventories, remaining shelf-life, and current market conditions to determine whether inventories are stated at the lower of cost and net realizable value. Inventories at our diagnostics segment consist primarily of purchased laboratory supplies, which are used in our testing laboratories. Inventory obsolescence expense for the three months ended March 31, 2023, was$0.4 million and $1.4 million, respectively.

Goodwill and intangible assets. Goodwill represents the difference between the purchase price and the estimated fair value of the net assets acquired accounted for by the acquisition method of accounting. Refer to Note 5. Goodwill, in-process research and development (“IPR&D”) and other intangible assets acquired in business combinations, licensing and other transactions was $1.4 billion and $1.5 billion at March 31, 2024 and December 31, 2023, respectively.

Assets acquired and liabilities assumed in business combinations, licensing and other transactions are generally recognized at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recognized as goodwill. At acquisition, we generally determine the fair value of intangible assets, including IPR&D, using the “income method.”

Subsequent to their acquisition, goodwill and indefinite lived intangible assets are tested at least annually as of October 1 for impairment, or when events or changes in circumstances indicate it is more likely than not that the carrying amount of such assets may not be recoverable.

Estimating the fair value of a reporting unit for goodwill impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment. We perform sensitivity analyses around our assumptions in order to assess the reasonableness of the assumptions and the results of our testing. Ultimately, potential changes in these assumptions may impact the estimated fair value of a reporting unit and result in an impairment if the fair value of such reporting unit is less than its carrying value. Goodwill was $530.6 million and $598.3 million, respectively, at March 31, 2024 and December 31, 2023.

13

Net intangible assets other than goodwill were $0.9 billion on each of March 31, 2024, and December 31, 2023, with IPR&D accounting for $195.0 million on each date. Considering the high risk nature of research and development and the industry’s success rate of bringing developmental compounds to market, IPR&D impairment charges may occur in future periods. Estimating the fair value of IPR&D for potential impairment is highly sensitive to changes in projections and assumptions and changes in assumptions could potentially lead to impairment.

Upon regulatory approval, IPR&D assets are classified as finite-lived intangible assets. These assets are then amortized on a straight-line basis over their estimated useful lives. If a project is abandoned, the associated IPR&D costs are immediately expensed. We also regularly assess finite-lived intangible assets for impairment. This assessment involves comparing the carrying amount of an asset, which is its cost minus accumulated amortization, to its estimated future undiscounted cash flows. If the carrying amount exceeds the estimated future cash flows, an impairment charge is recognized to reflect the difference between the asset's carrying amount and its fair value.

While we believe our estimates and assumptions used in impairment testing (including for goodwill and IPR&D) are reasonable and reflect those used by market participants, there is a potential risk of material impairment charges. Based on the current financial performance of our diagnostics segment and our Ireland reporting unit (which includes Eirgen and Rayaldee), we could be subject to such charges if their future performance deviates from our current estimates and assumptions. For reference, the combined goodwill of these units totaled $300.2 million and $367.3 million at March 31, 2024 and December 31, 2023, respectively.

We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives, ranging from 3 to 20 years. We use the straight-line method of amortization as there is no reliably determinable pattern in which the economic benefits of our intangible assets are consumed or otherwise used up. Amortization expense was $21.4 million and $21.5 million for the three months ended March 31, 2024, and 2023, respectively.

Fair value measurements. The carrying amounts of our cash and cash equivalents, accounts receivable, accounts payable and short-term debt approximate their fair value due to the short-term maturities of these instruments. Investments that are considered equity securities as of March 31, 2024 and December 31, 2023 are predominately carried at fair value. Our debt under the Credit Agreement (as defined below) approximates fair value due to the variable rate of interest applicable to such debt.

In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. Refer to Note 9.

Contingent consideration. Each period we revalue the contingent consideration obligations associated with certain prior acquisitions to their fair value and record increases in the fair value as contingent consideration expense and decreases in the fair value as a reduction in contingent consideration expense. Changes in contingent consideration result from changes in the assumptions regarding probabilities of successful achievement of related milestones, the estimated timing in which the milestones are achieved and the discount rate used to estimate the fair value of the liability. Contingent consideration maychange significantly as our development programs progress, revenue estimates evolve and additional data is obtained, impacting our assumptions. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value which mayhave a material impact on our results from operations and financial position.

Derivative financial instruments. We record derivative financial instruments on our Condensed Consolidated Balance Sheet at their fair value and recognize the changes in the fair value in our Condensed Consolidated Statement of Operations when they occur, the only exception being derivatives that qualify as hedges. For the derivative instrument to qualify as a hedge, we are required to meet strict hedge effectiveness and contemporaneous documentation requirements at the initiation of the hedge and assess the hedge effectiveness on an ongoing basis over the life of the hedge. At March 31, 2024 and December 31, 2023, our foreign currency forward contracts held to economically hedge inventory purchases did not meet the documentation requirements to be designated as hedges. Accordingly, we recognized all changes in the fair values of our derivatives instruments, net, in our Condensed Consolidated Statement of Operations. Refer to Note 10. In addition, we have determined the value of the embedded derivative liability within the 2029 Convertible 144A Notes and recorded it at fair value. Refer to Note 7. The changes in the fair value of the embedded derivatives are recognized in the fair value changes of derivatives instruments, net. Refer to Note 9.

14

Property, plant and equipment. Property, plant and equipment are recorded at cost or fair value if acquired in a business combination. Depreciation is provided using the straight-line method over the estimated useful lives of the assets and includes amortization expense for assets capitalized under finance leases. The estimated useful lives by asset class are as follows: software - 3 years, machinery, medical and other equipment - 5-8 years, furniture and fixtures - 5-12 years, leasehold improvements - the lesser of their useful life or the lease term, buildings and improvements - 10-40 years, and automobiles - 3-5 years. Expenditures for repairs and maintenance are charged to expense as incurred. Assets held under finance leases are included within Property, plant and equipment, net in our Condensed Consolidated Balance Sheets and are amortized over the shorter of their useful lives or the expected term of their related leases. Depreciation expense was $4.4 million and$5.0 million for the three months ended March 31, 2024, and 2023, respectively.

Impairment of long-lived assets. Long-lived assets, such as property and equipment and assets held for sale, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, then an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset.

Income taxes. Income taxes are accounted for under the asset-and-liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases and for operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. We periodically evaluate the realizability of our net deferred tax assets. Our tax accruals are analyzed periodically and adjustments are made as events occur to warrant such adjustment. Valuation allowances on certain U.S. deferred tax assets and non-U.S. deferred tax assets are established, because realization of these tax benefits through future taxable income does not meet the more-likely-than-not threshold.

We operate in various countries and tax jurisdictions globally. For interim reporting purposes, we record income taxes based on the expected effective income tax rate, taking into consideration year to date and global forecasted tax results.For the three months ended March 31, 2024, the tax rate differed from the U.S. federal statutory rate of 21% primarily due to the valuation allowance against certain U.S. and non-U.S. deferred tax assets, the relative mix in earnings and losses in the U.S. versus foreign tax jurisdictions, and the impact of certain discrete tax events and operating results in tax jurisdictions which do not result in a tax benefit.

Included in Other long-term liabilities is an accrual of $9.9 million related to uncertain tax positions involving income recognition. In connection with an examination of foreign tax returns for the 2015 through 2021 tax years, a foreign taxing authority has issued an income tax assessment of approximately $246million (including interest). We are appealing this assessment, as we believe, other than for uncertain tax positions for which we have reserved, the issues are without technical merit. We intend to exhaust all judicial remedies necessary to resolve the matter as necessary,which could be a lengthy process. There can be no assurance that this matter will be resolved in our favor, and an adverse outcome, or any future tax examinations involving similar assertions, could have a material adverse effect on our financial condition, results of operations and cash flows.

Revenue recognition. We recognize revenue when a customer obtains control of promised goods or services in accordance with Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“TDZ辱 606”). The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation.

We apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of Topic 606, we review the contract to determine which performance obligations we must deliver and which of these performance obligations are distinct. We recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. For a complete discussion of accounting for Revenues from services, Revenues from products and Revenue from transfer of intellectual property and other, refer to Note 13.

Concentration of credit risk and allowance for credit losses. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.

15

While we have receivables due from federal and state governmental agencies, such receivables are not a credit risk because federal and state governments fund the related healthcare programs. Payment is primarily dependent upon submitting appropriate documentation. On March 31, 2024 and December 31, 2023, receivable balances (net of explicit and implicit price concessions) from Medicare and Medicaid were 7.4% and 6.7%, respectively, of our consolidated Accounts receivable, net. The portion of our accounts receivable due from individual patients comprises the largest portion of credit risk. At March 31, 2024 and December 31, 2023, receivables due from patients represented approximately 2.2% and 2.0%, respectively, of our consolidated Accounts receivable, net.

We assess the collectability of accounts receivable balances by considering factors such as historical collection experience, customer credit worthiness, the age of accounts receivable balances, regulatory changes and current economic conditions and trends that may affect a customer’s ability to pay. Actual results could differ from those estimates. The allowance for credit losses was $2.0 million on each of March 31, 2024, and December 31, 2023. The credit loss expense for the three months ended March 31, 2024 and 2023, was $128.6 thousand and $85.2 thousand, respectively.

As of March 31, 2024, accounts receivable included $0.8 million of revenue earned under the BARDA Contract (as defined in Note 14). As of December 31, 2023, accounts receivable included $0.6 million under this contract. Refer to Note 13, Government Contract Revenue for further information on government contracts and to Note 14, Strategic Alliances for further information on the BARDA Contract.

Equity-based compensation. We measure the cost of services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized in the Condensed Consolidated Statement of Operations over the period during which an employee is required to provide service in exchange for the award. We record excess tax benefits realized from the exercise of stock options as cash flows from operations. For the three months ended March 31, 2024, and 2023, we recorded $2.6 million and $2.7 million, respectively, of equity-based compensation expense.

Research and development expenses. Research and development expenses include external and internal expenses. External expenses include clinical and nonclinical activities performed by contract research organizations, lab services, purchases of drug and diagnostic product materials and manufacturing development costs. Research and development employee-related expenses include salaries, benefits and equity-based compensation expense. Other internal research and development expenses are incurred to support overall research and development activities and include expenses related to general overhead and facilities. We expense these costs in the period in which they are incurred. We estimate our liabilities for research and development expenses in order to match the recognition of expenses to the period in which the actual services are received. As such, accrued liabilities related to third party research and development activities are recognized based upon our estimate of services received and degree of completion of the services in accordance with the specific third party contract.

Research and development expense includes costs for in-process research and development projects acquired in asset acquisitions which have not reached technological feasibility, and which have no alternative future use. For in-process research and development projects acquired in business combinations, the in-process research and development project is capitalized and evaluated for impairment until the development process has been completed. Once the development process has been completed the asset will be amortized over its remaining estimated useful life.

Segment reporting. Our chief operating decision-makeris Phillip Frost, M.D., our Chairman and Chief Executive Officer. Dr. Frost reviews our operating results and operating plans and makes resource allocation decisions on a Company-wide or aggregate basis. We manage our operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of our pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, Rayaldee product sales and our pharmaceutical research and development. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and our point-of-care operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense or income taxes. Refer to Note 15.

Shipping and handling costs. We do not charge customers for shipping and handling costs. Shipping and handling costs are classified as Cost of revenues in the Condensed Consolidated Statement of Operations.

Foreign currency translation. The financial statements of certain of our foreign operations are measured using the local currency as the functional currency. The local currency assets and liabilities are generally translated at the rate of exchange to the U.S. dollar on the balance sheet date. The local currency revenues and expenses are translated at average rates of exchange to the U.S. dollar during the reporting periods. Foreign currency transaction gains (losses) have been reflected as a component of Other income (expense), net within the Condensed Consolidated Statement of Operations and foreign currency translation gains (losses) have been included as a component of the Condensed Consolidated Statement of Comprehensive Income (Loss). During the three months ended March 31, 2024 and 2023, we recorded foreign currency transaction gains and (losses) of ($2.7 million) and $1.0 million, respectively.

16

Variable interest entities. The consolidation of a variable interest entity (“VIE”) is required when an enterprise has a controlling financial interest. A controlling financial interest in a VIE will have both of the following characteristics: (a) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance and (b) the obligation to absorb losses of the VIE that could potentially be significant to the VIE. Refer to Note 6.

Investments. We have made strategic investments in development stage and emerging companies. We record these investments as equity method investments or as equity securities based on our percentage of ownership and whether we have significant influence over the operations of the investees. For investments classified under the equity method of accounting, we record our proportionate share of their losses in Losses from investments in investees in our Condensed Consolidated Statement of Operations. Refer to Note 6. For investments classified as equity securities, we record changes in their fair value as Other income (expense) in our Condensed Consolidated Statement of Operations based on their closing price per share at the end of each reporting period, unless the equity security does not have a readily determinable fair value. Refer to Note 6.

Accounting standards yet to be adopted.

In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures” (“ASU 2023-09”), which modifies the rules on income tax disclosures to require entities to disclose (i) specific categories in the rate reconciliation, (ii) the income or loss from continuing operations before income tax expense or benefit (separated between domestic and foreign) and (iii) income tax expense or benefit from continuing operations (separated by federal, state and foreign). ASU 2023-09 also requires entities to disclose their income tax payments to international, federal, state, and local jurisdictions, among other changes. The guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. ASU 2023-09 should be applied on a prospective basis, but retrospective application is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.

In November 2023, the FASB issued ASU No 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”). ASU 2023-07 enhances disclosures for significant segment expenses for all public entities required to report segment information in accordance with ASC 280. ASC 280 requires a public entity to report for each reportable segment a measure of segment profit or loss that its chief operating decision maker (“CODM”) uses to assess segment performance and to make decisions about resource allocations. The amendments in ASU 2023-07 improve financial reporting by requiring all public entities to disclose incremental segment information on an annual and interim basis to enable investors to develop more useful financial analyses. Topic 280 requires that a public entity disclose certain information about its reportable segments, for example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. ASC 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The ASU 2023-07 amendments do not change or remove those disclosure requirements. The amendments in ASU 2023-07 also do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. Upon adoption, a public entity must retrospectively apply ASU 2023-07 amendments to all prior periods presented in the financial statements. The amendments in ASU 2023-07 are effective for all public entities for fiscal years beginning after December 15, 2023 (e.g., for calendar-year-end public entities, annual periods beginning on January 1, 2024 — i.e., December 31, 2024, Form 10-K), and interim periods within fiscal years beginning after December 15, 2024 (e.g., for calendar-year-end public entities, interim periods beginning on January 1, 2025 — i.e., Form 10-Q for the first quarter of 2025). Early adoption is permitted. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures.

Recently adopted accounting standards.

In 2021, the Organization for Economic Co-operation and Development (“OECD”) established an inclusive framework on base erosion and profit shifting and agreed on a two-pillar solution (“Pillar Two”) to global taxation, focusing on global profit allocation and a 15% global minimum effective tax rate. On December 15, 2022, the EU member states agreed to implement the OECD’s global minimum tax rate of 15%. The OECD issued Pillar Two model rules and continues to release guidance on these rules. The inclusive framework calls for tax law changes by participating countries to take effect in 2024 and 2025. Various countries have enacted or have announced plans to enact new tax laws to implement the global minimum tax. We considered the applicable tax law changes on Pillar Two implementation in the relevant countries, and there is no material impact to our tax results for the period. We anticipate further legislative activity and administrative guidance in 2024, and will continue to evaluate the impacts of enacted legislation and pending legislation to enact Pillar Two Model Rules in the non-US tax jurisdictions we operate in.

17

NOTE 4 EARNINGS (LOSS) PER SHARE

Basic income (loss) per share is computed by dividing our net income (loss) by the weighted average number of shares of our Common Stock outstanding during the period. Shares of Common Stock outstanding under theshare lendingarrangement entered into in conjunction with the 2025 Notes (as defined in Note 7) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent. Refer to Note 7. For diluted earnings per share, the dilutive impact of stock options and warrants is determined by applying the “treasury stock” method. The dilutive impact of the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes (each, as defined and discussed in Note 7) has been considered using the “if converted” method. For periods in which their effect would have been antidilutive, no effect is given to Common Stock issuable under outstanding options or warrants or the potentially dilutive shares issuable pursuant to the 2029 Convertible Notes, 2033 Senior Notes, the 2023 Convertible Notes and the 2025 Notes in the dilutive computation.

A total of 296,587,793 and 82,441,440 potential shares of Common Stock were excluded from the calculation of diluted net loss per share for the three months ended March 31, 2024 and 2023, respectively, because their inclusion would have been antidilutive. A full presentation of diluted earnings per share has not been provided because the required adjustments to the numerator and denominator resulted in diluted earnings per share equivalent to basic earnings per share.

During the three months ended March 31, 2024, no options were exercised and no restricted stock units vested, resulting in the issuance of no shares of Common Stock.

During the three months ended March 31, 2023, no options were exercised and no restricted stock units vested, resulting in the issuance of no shares of Common Stock.

18

NOTE 5 COMPOSITION OF CERTAIN FINANCIAL STATEMENT CAPTIONS

March 31,

December 31,

(In thousands)

2024

2023

Accounts receivable, net:

Accounts receivable

$ 113,360 $ 125,379

Less: allowance for credit losses

(1,993 ) (2,000 )
$ 111,367 $ 123,379

Inventories, net:

Consumable supplies

$ 19,346 $ 35,582

Finished products

34,008 25,864

Work in-process

3,286 1,731

Raw materials

8,246 8,981

Less: inventory reserve

(5,520 ) (6,461 )
$ 59,366 $ 65,697

Other current assets and prepaid expenses:

Taxes recoverable

$ 3,674 $ 4,211

Prepaid expenses

8,649 6,177

Prepaid insurance

1,538 3,848

Other receivables

4,165 2,610

Other

6,626 7,673
$ 24,652 $ 24,519

Intangible assets, net:

Customer relationships

$ 256,732 $ 315,799

Technologies

813,234 831,509

Trade names

49,739 49,758

Covenants not to compete

12,912 12,916

Licenses

6,259 6,205

Product registrations

6,331 6,790

Other

5,899 6,000

Less: accumulated amortization

(471,072 ) (488,694 )
$ 680,034 $ 740,283

Accrued expenses:

Employee benefits

$ 31,264 $ 28,952

Clinical trials

6,077 7,624

Commitments and contingencies

8,642 8,088

Gross to net provision

6,082 9,420

Inventory received but not invoiced

2,972 1,653

Finance leases short-term

1,783 2,827

Professional fees

2,571 3,470

Taxes payable

3,751 1,384

Royalties

1,705 1,544

Commissions

1,877 1,822

Other

22,048 23,302
$ 88,772 $ 90,086

Other long-term liabilities:

Mortgages and other debts payable

$ 4,036 $ 7,709

Finance leases long-term

4,987 7,274

Contract liabilities

7 7

Other

12,166 12,199
$ 21,196 $ 27,189

19

Our intangible assets and goodwill relate principally to our completed acquisitions of OPKO Renal, OPKO Biologics, EirGen, BioReference and ModeX. We amortize intangible assets with definite lives on a straight-line basis over their estimated useful lives. The estimated useful lives by asset class are as follows: technologies - 7-17 years, customer relationships - 5-20 years, product registrations - 7-10 years, covenants not to compete - 5 years, trade names - 5-10 years, other 9-13 years. We do not anticipate capitalizing the cost of product registration renewals, rather we expect to expense these costs, as incurred. Our goodwill is not tax deductible for income tax purposes in any jurisdiction in which we operate.

Changes in value of the intangible assets and goodwill during thethree months ended March 31, 2024 and 2023 were primarily due to foreign currency fluctuations between the Euro, and the Chilean Peso against the U.S. dollar.

The following table summarizes the changes in Goodwill by reporting unit during the three months ended March 31, 2024.

2024

(In thousands)

Gross goodwill at January 1

Cumulative impairment at January 1

Acquisitions, dispositions and other

Foreign exchange and other

Balance at March 31

Pharmaceuticals

CURNA

$ 4,827 $ (4,827 ) $ $ $

Rayaldee

84,273 (1,816 ) 82,457

FineTech

11,698 (11,698 )

ModeX

80,260 80,260

OPKO Biologics

139,784 (0 ) 139,784

OPKO Chile

3,642 (374 ) 3,268

˹ Europe

7,276 (161 ) 7,115

OPKO Mexico

100 (100 )

Transition Therapeutics

3,421 (3,421 )

Diagnostics

BioReference

283,025 (65,294 ) 217,731

OPKO Diagnostics

17,977 (17,977 )
$ 636,283 $ (38,023 ) $ (65,294 ) $ (2,351 ) $ 530,615

Acquisitions, disposition and other includes amounts related to the Labcorp Asset Purchase Agreement, which is included in assets held for sale at March 31, 2024.

NOTE 6 INVESTMENTS

Investments

The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of March 31, 2024 and December 31, 2023:

(in thousands)

As of March 31, 2024

As of December 31, 2023

Investment type

Investment Carrying Value

Underlying Equity in Net Assets

Investment Carrying Value

Underlying Equity in Net Assets

Equity method investments

$ (0 ) $ 2,734 $ (0 ) $ 2,942

Variable interest entity, equity method

793 157 796 420

Equity method investments - FV option

32,490 9,786

Equity securities

183 116

Equity securities with no readily determinable fair value

7,521 5,382

Warrants and options

3 2

Total carrying value of investments

$ 40,990 $ 16,082

20

Equity method investments

Our equity method investments, other than in GeneDx Holdings, as describedbelow, consist of investments in Pharmsynthez (ownership 9%), Cocrystal Pharma, Inc. (“COCP”) (2%), Non-Invasive Monitoring Systems, Inc. (“NIMS”) (1%), BioCardia, Inc. (“BioCardia”) (1%), Xenetic Biosciences, Inc. (“Xenetic”) (3%), and LeaderMed Health Group Limited (“LeaderMed”) (47%). Neovasc, Inc., in which we owned a 0.5% interest, was acquired by Shockwave Medical, Inc. in April 2023. As a result, we received $363 thousand in merger consideration in exchange for our shares. The aggregate amount of assets, liabilities, and net losses of these equity method investees as of and for thethree months ended March 31, 2024 were $80.4 million, $23.6 million, and $9.3 million, respectively. The aggregate amount of assets, liabilities, and net losses of our equity method investees as of and for the year ended December 31, 2023 were $85.5 million, $20.8 million, and $37.7 million, respectively. We have determined that we or our related parties have the ability to exercise significant influence over our equity method investments through our board representation or voting power. Accordingly, we account for our investment in these entities under the equity method and record our proportionate share of their losses in Loss from investments in investees in our Consolidated Statement of Operations. The aggregate value of our equity method investments based on the quoted market prices of their respective shares of common stock and the number of shares held by us as of March 31, 2024 and December 31, 2023 was $0.6 million and $0.7 million, respectively.

Equity method investments - Fair value option

On January 14, 2022,the Company entered into an Agreement and Plan of Merger and Reorganization (the “GeneDx Merger Agreement”) with GeneDx Holdings Corp. (f/k/aSema4Holdings Corp.), a Delaware corporation (“GeneDx Holdings”), pursuant to which GeneDx Holdings acquired our former subsidiary, GeneDx LLC (formerly GeneDx, Inc. “GeneDx”), on April 28, 2022. As a result of this transaction, the Company holds an equity method investment in GeneDx Holdings, representing an approximate13.7% ownership interest. Pursuant to the GeneDx Merger Agreement, the Company designated, and GeneDx Holdings nominated for election an individual to serve on the board of directors of GeneDx Holdings, and such nominee was elected by GeneDx Holdings stockholders to serve as a director until GeneDx Holdings2024annual meeting of stockholders. Therefore, we have determined that the Company or our related parties can exercise significant influence over the investee through our board representation or voting power.However, our influence is limited by the GeneDx Holdings Shareholder Agreement, pursuant to which we have agreed to vote our shares of GeneDx Holdings Common Stock in accordance with the recommendation of GeneDx Holdings' board of directors for so long as we continue to hold at least 5% of the outstanding shares of GeneDx Holdings common stock. Other than through our sole board seat, we are unable to influence GeneDx Holdings' policy-making process. We currently holdoneofsevenseats on the GeneDx Holdings board of directors, and our designee maycontinue to serve following the expiration of the lock-up period if re-elected by GeneDx Holdings stockholders.

We elected to account for our investment in GeneDx Holdings under the equity method fair value option and record gains and losses from changes in fair value in other income (expense), net in our Condensed Consolidated Statements of Operations. For the three months ended March 31, 2024 and 2023, we recognized $22.7 million and $8.3 million in net income related to the change in fair value of our GeneDx Holdings investment, respectively. As of March 31, 2024,the aggregate value of our GeneDx Holdings investment based on the quoted market price of the GeneDx Holdings Common Stock was $32.5 million.

Investments in equity securities

Our equity securities consist of investments in VBI Vaccines Inc.(0.19%), ChromaDex Corporation (“ChromaDex”) (0.05%), and Eloxx Pharmaceuticals, Inc. (“Eloxx”) (1%). Our equity securities without readily determinable fair value consists of CAMP4 Therapeutics Corporation (“Cѱ4”) (2%) and HealthSnap, Inc. (4%). We have determined that our ownership, along with that of our related parties, does not provide us with significant influence over the operations of these investments. Accordingly, we account for our investment in these entities as equity securities, and we record changes in the fair value of these investments in Other income (expense) each reporting period when they have readily determinable fair value. Equity securities without a readily determinable fair value are adjusted to fair value when there is an observable price change. Net gains and losses on our equity securities for thethree months ended March 31, 2024 and 2023 were as follows:

For the three months ended March 31,

(in thousands)

2024

2023

Equity Securities:

Net gains and losses recognized during the period on equity securities

$ 67 $ (105 )

Unrealized net losses recognized during the period on equity securities still held at the reporting date

$ 67 $ (105 )

21

Sales of investments

Gains (losses) included in earnings from sales of our investments are recorded in Other income (expense), net in our Condensed Consolidated Statement of Operations. The cost of securities sold is based on the specific identification method.

Warrants and options

In addition to our equity method investments and equity securities, we hold options to purchase 47 thousand additional shares of BioCardia, all of which were vested as of March 31, 2024 and December 31, 2023, and warrants to purchase 33 thousand and 0.7 million additional shares of COCP and InCellDx Inc., respectively. We recorded the changes in the fair value of the options and warrants in fair value changes of derivative instruments, net in our Condensed Consolidated Statement of Operations. We also recorded the fair value of the options and warrants in Investments, net in our Condensed Consolidated Balance Sheet. See further discussion of the Company’s options and warrants in Note 9 and Note 10.

Investments in variable interest entities

We have determined that we hold variable interests in LeaderMed and Zebra Biologics, Inc. (“Zebra”). We made this determination as a result of our assessment that they do not have sufficient resources to carry out their principal activities without additional financial support.

In September 2021, we and LeaderMed, a pharmaceutical development company with operations based in Asia, formed a joint venture to develop, manufacture and commercialize two of OPKO’s clinical stage, long-acting drug products in Greater China and eight other Asian territories. Under the terms of the agreements, we granted the joint venture exclusive rights to develop, manufacture and commercialize (a) OPK88003, an oxyntomodulin analog being developed for the treatment of obesity and diabetes, and (b) Factor VIIa-CTP, a novel long acting coagulation factor being developed to treat hemophilia, in exchange for 4,703 shares 47% ownership interest in the joint venture. In addition, we received an upfront payment of $1.0million and will be reimbursed for clinical trial material and technical support we provide the joint venture.

In order to determine the primary beneficiary of the joint venture, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related parties’ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of the joint venture. Based on the capital structure, governing documents and overall business operations of the joint venture, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact the joint venture’s economic performance and do not have an obligation to fund expected losses. We did determine that we can significantly influence control of the joint venture through our board representation and voting power. Therefore, we have the ability to exercise significant influence over the joint venture’s operations and account for our investment in the joint venture under the equity method.

22

We own 1,260,000 shares of Zebra’s Series A-2 Preferred Stock and 900,000 shares of Zebra restricted common stock (ownership 29%) at March 31, 2024 and December 31, 2023). Zebra is a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drugs. Dr. Richard Lerner, M.D., a former member of our Board of Directors, was a founder of Zebra.Dr. Frostserves as a member of Zebra’s Board of Directors.

In order to determine the primary beneficiary of Zebra, we evaluated our investment and our related parties’ investment, as well as our investment combined with the related parties’ investment to identify if we had the power to direct the activities that most significantly impact the economic performance of Zebra. Based on the capital structure, governing documents and overall business operations of Zebra, we determined that, while a VIE, we do not have the power to direct the activities that most significantly impact Zebra’s economic performance and have no obligation to fund expected losses. We determined, however, that we can significantly influence control of Zebra through our board representation and voting power. Therefore, we have the ability to exercise significant influence over Zebra’s operations and account for our investment in Zebra under the equity method.

NOTE 7 DEBT

As of March 31, 2024 and December 31, 2023, our debt consisted of the following:

March 31,

December 31,

(In thousands)

2024

2023

2029 Convertible Notes

$ 323,058 $

2025 Convertible Notes

170 143,250

2033 Senior Notes

50 50

2023 Convertible Notes

71,025

JP Morgan Chase

11,668 12,671

Chilean and Spanish lines of credit

9,330 12,629

Current portion of notes payable

1,822 1,992

Long term portion of notes payable

4,036 7,727

Total

$ 350,134 $ 249,345

Balance sheet captions

Current portion of convertible notes

$ 170 $

Long term portion of convertible notes

323,108 214,325

Current portion of lines of credit and notes payable

22,820 27,293

Long Term notes payable included in long-term liabilities

4,036 7,727

Total

$ 350,134 $ 249,345

In January 2024,we completed a private offering of $230.0million aggregate principal amount of our3.75% Convertible Senior Notes due2029(the“2029Convertible 144A Notes”) in accordance with the terms of a note purchase agreement (the“144Note Purchase Agreement”) entered into by and between the Company and J.P. Morgan Securities LLC (the “Initial Purchaser”). The $230.0million aggregate principal amount of2029Convertible 144A Notes includes $30.0million aggregate principal amount of2029Convertible144ANotes purchased on the closing date by the Initial Purchaser in accordance with its exercise in full of its overallotment option.

Net proceeds from the 2029 Convertible 144A Notes issuance totaled approximately $222.0 million after deducting fees and estimated offering expenses payable by us. We allocated approximately $50.0 million of these net proceeds to repurchase shares of our Common Stock. These repurchases were from purchasers of the 2029 Convertible 144A Notes in privately negotiated transactions effected with or through the Initial Purchaser or its affiliate. The purchase price per share of the Common Stock in these transactions equaled the closing sale price of $0.9067 per share of Common Stock on January 4, 2024.

Contemporaneously with the closing of the offering of the 2029 Convertible 144A Notes on January 9, 2024, we issued and sold approximately $71.1 million aggregate principal amount of our 3.75% Convertible Senior Notes due 2029 (the “2029 Convertible Affiliate Notes” and, together with the 2029 Convertible 144A Notes, the “2029 Convertible Notes”) pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the “Affiliate Note Purchase Agreement”) by and among the Company and certain investors including, Frost Gamma Investments Trust, a trust controlled by Dr. Phillip Frostand Dr. Jane H. Hsiao(collectively, the “Affiliate Purchasers”). Pursuant to the Affiliate Note Purchase Agreement, we issued and sold the 2029 Convertible Affiliate Notes to the Affiliate Purchasers in exchange for the entirety of the $55.0 million aggregate principal amount of our outstanding 2023 Convertible Notes held by the Affiliate Purchasers, together with approximately $16.1 million of accrued but unpaid interest thereon.

23

On January 9th, 2024, we recorded the $125.6 million value of the embedded derivative liability within the 2029 Convertible Notes as a debt discount. To determine the fair value of this derivative, we employed the Binomial Lattice model. Key inputs and assumptions for this valuation included our common stock price, the derivative's exercise price, risk-free interest rate, volatility, annual coupon rate, and remaining contractual term. We are amortizing the debt discount as non-cash interest expense over the term of the Notes.

From the date the Notes were issued through March 31, 2024, we observed an increase in the market price of our Common Stock which resulted in a $26.25 million increase in the estimated fair value of our embedded derivatives recorded in Fair value changes of derivative instruments, net in our Condensed Consolidated Statements of Operations.

Holders mayconvert their2029Convertible Notes at their option prior to the close of business on the business day immediately preceding September 15, 2028only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2024 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least20trading days (whether ornotconsecutive) during the period of30consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to130% of the applicable conversion price on each applicable trading day; (2) during thefiveconsecutive business day period after anytenconsecutive trading day period (the “convertible note measurement period”) in which the trading price per$1,000principal amount of notes for each trading day of the convertible note measurement period was less than98% of the product of the last reported sale price of our Common Stock and the applicable conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events specified in the indenture governing the2029Convertible Notes. On or after September 15, 2028until the close of business on the business day immediately preceding the maturity date, holders mayconvert their notes at any time, regardless of the foregoing conditions. Upon conversion of a note, we will pay or deliver, as the case maybe, cash, shares of our Common Stock or a combination of cash and shares of our Common Stock, at our election.

The conversion rate is initially equal to869.5652shares of Common Stock per$1,000principal amount of notes (equivalent to an initial conversion price of approximately $1.15per share of Common Stock). The conversion rate for the2029Convertible Notes will be subject to adjustment upon the occurrence of certain events but willnotbe adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date of the notes,in certain circumstances we will increase the conversion rate of the2029Convertible Notesfor a holder who elects to convert its notes in connection with such a corporate event.

We maynotredeem the notes prior to the maturity date, andnosinking fund is provided for the notes. If we undergo a fundamental change, holders mayrequire us to purchase the notes in whole or in part for cash at a fundamental change purchase price equal to100% of the principal amount of the notes to be purchased,plusaccrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date. The2029Convertible Notes areour senior unsecured obligations andrank senior in right of payment to any indebtedness that is expressly subordinated in right of payment to the notes, and equal in right of payment with all of our existing and future unsecured indebtedness that isnotso subordinated. The notes are effectively subordinated to all of our existing and future secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally subordinated to all existing and future liabilities (including trade payables) of our subsidiaries (including, without limitation, liabilities of our subsidiaries under theCredit Agreement).

24

The indenture governing the notes provides for customary events of default which include (subject in certain cases to customary grace and cure periods), among others, the following: nonpayment of principal or interest; breach of covenants or other agreements in the indenture; defaults in failure to pay certain other indebtedness; judgment defaults; and certain events of bankruptcy or insolvency. Generally, if an event of default occurs and is continuing under the indenture, the trustee thereunder or the holders of at least25%in aggregate principal amount of the notes then outstanding maydeclare100%of the principal of and accrued and unpaid interest, if any on all then-outstanding notes to be immediately due and payable. In certain circumstances, we may,for a period of time, elect to pay additional interest on the notes as the sole remedy to holders of the notes in the case of an event of default related to certain failures by us to comply with certain reporting covenants in the indenture.

The following table sets forth information related to the2029Convertible Notes which is included in our Condensed Consolidated Balance Sheet as of March 31, 2024:

(In thousands)

2029 convertible notes

Embedded conversion option

Discount

Debt Issuance costs

Total

Balance at December 31, 2023

$ $ $ $ $

Issuance of 3.75% 2029 Convertible Notes

301,054 125,620 (125,620 ) (8,562 ) 292,492

Amortization of debt discount and debt issuance costs

3,815 501 4,316

Change in fair value of embedded derivative

26,250 26,250

Balance at March 31, 2024

$ 301,054 $ 151,870 $ (121,805 ) $ (8,061 ) $ 323,058

In February 2019, we issued $200.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “2025 Notes”) in an underwritten public offering. The 2025 Notes bear interest at a rate of 4.50% per year, payable semiannually in arrears on February15 and August15 of each year. The 2025 Notes mature on February15, 2025, unless earlier repurchased, redeemed or converted.

In May 2021,we entered into the Exchange (as defined below) with certain holders of the2025Notes pursuant to which the holders exchanged $55.4million in aggregate principal amount of the outstanding2025Notes for19,051,270shares of our Common Stock (the “Exchange”).

Contemporaneously with the closing of our offering of the2029Convertible Notes,we repurchased approximately $144.4million aggregate principal amount of the2025Notes for cash, using $146.3million of the net proceeds from our issuance and sale of the2029Convertible Notes, following which only $170thousand aggregate principal amount of the2025Notes remained outstanding.

Holders mayconvert their2025Notes into shares of Common Stock at their option at any time prior to the close of business on the business day immediately preceding November 15, 2024only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended March 31, 2019 (and only during such calendar quarter), if the last reported sale price of our Common Stock for at least20trading days (whether ornotconsecutive) during a period of30consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to130% of the conversion price on each applicable trading day; (2) during thefivebusiness day period after anyfiveconsecutive trading day period (the “measurement period”) in which the trading price per$1,000principal amount of2025Notes for each trading day of the measurement period was less than98% of the product of the last reported sale price of our Common Stock and the conversion rate on each such trading day; (3) if we call any or all of the2025Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events set forth in the indenture governing the2025Notes. On or after November 15, 2024,until the close of business on the business day immediately preceding the maturity date, holders of the2025Notes mayconvert their notes at any time, regardless of the foregoing conditions. Upon conversion, we will pay or deliver, as the case maybe, cash, shares of our Common Stock, or a combination of cash and shares of our Common Stock, at our election.

On January 22, 2024, we terminated our share lending agreement, dated February 4, 2019, with Jefferies Capital Services, LLC (“Share Borrower”). Through this agreement, we had lent the Share Borrower approximately 30 million shares of our common stock related to our 2019 issuance of the $200.0 million in 2025 Notes. With the termination of this agreement, all remaining borrowed shares of Common Stock have been returned to us and are now held as treasury shares.

25

In February 2018, we issued a series of 5% Convertible Promissory Notes (the “2023 Convertible Notes”) in the aggregate principal amount of $55.0 million. The original maturity of the 2023 Convertible Notes was five years following the date of issuance. Each holder of a 2023 Convertible Note originally had the option, from time to time, to convert all or any portion of the outstanding principal balance of such 2023 Convertible Note, together with accrued and unpaid interest thereon, into shares of our Common Stock at a conversion price of $5.00 per share.

On February 10, 2023, we amended the 2023 Convertible Notes to extendthe maturity to January 31, 2025 and reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66 per share. Interest under the 2023 Convertible Notes accrued from the most recent date to which interest has been paid or, if no interest has been paid, from the date of issuance, until the principal and accrued and unpaid interest, are paid in full. Purchasers of the 2023 Convertible Notes included an affiliate of Dr. Phillip Frost, M.D., our Chairman and Chief Executive Officer, and Dr. Jane H. Hsiao, Ph.D., MBA, our Vice-Chairman and Chief Technical Officer.

In connection with the closing of the 2029 Convertible Notes offering, the Company issued approximately $71.1 million aggregate principal amount of its 2029 Convertible Affiliate Notes pursuant to a separate Affiliate Note Purchase Agreement. Following this exchange, no 2023 Convertible Notes remained outstanding. See above section on the 2029 Convertible Affiliate Agreement for further information.

In January 2013,we issued an aggregate of $175.0million of our3.0% Senior Notes due2033(the“2033Senior Notes”) in a private placement. The2033Senior Notes bearinterest at the rate of3.0% per year, payable semiannually on February 1and August 1of each year and matureon February 1, 2033,unless earlier repurchased, redeemed or converted. From2013to2016,holders of the2033Senior Notes converted $143.2million in aggregate principal amount into Common Stock, and, on February 1, 2019,approximately $28.8million aggregate principal amount of2033Senior Notes were tendered by holders pursuant to such holders’ option to require us to repurchase the2033Senior Notes. During the first quarter of 2023, we paid approximately $3.0million to purchase2033Senior Notes in accordance with the indenture governing the2033Senior Notes, following which $50.6thousand2033Senior Notes remained outstanding.

The terms of the2033Senior Notes, include, among others: (i) rights to convert the notes into shares of our Common Stock, including upon a fundamental change; and (ii) a coupon make-whole payment in the event of a conversion by the holders of the2033Senior Notes on or after February 1, 2017but prior to February 1, 2019.We determined that these specific terms were embedded derivatives. Embedded derivatives are required to be separated from the host contract, the2033Senior Notes, and carried at fair value when: (a) the embedded derivative possesses economic characteristics that arenotclearly and closely related to the economic characteristics of the host contract; and (b) a separate, stand-alone instrument with the same terms would qualify as a derivative instrument. We concluded that the embedded derivatives within the2033Senior Notes met these criteria and, as such, were valued separate and apart from the2033Senior Notes and recorded at fair value each reporting period.

In November 2015, BioReference and certain of its subsidiaries entered into a credit agreement with JPMorgan Chase Bank, N.A. (“CB”), as lender and administrative agent, as amended (the “Credit Agreement”). As amended, the Credit Agreement provides for a $75.0 million secured revolving credit facility and includes a $20.0 million sub-facility for swingline loans and a $20.0 million sub-facility for the issuance of letters of credit.

On June 29, 2023,the Company entered into an amendment to the Credit Agreement (the “Credit Agreement Amendment”), which, among other things, (i) replaced the London interbank offered rate (LIBOR) with the forward-looking term rate based on the secured overnight financing rate (the “SOFR Rate”) as the interest rate benchmark, (ii) reduced the aggregate revolving commitment from $75,000,000 to $50,000,000, (iii)provided a revised commitment fee rate, and (iv) extended the maturity date from August 2024to the earlier of August 2025,and90days prior to the maturity date of any indebtedness of the Company in an aggregate principal amount exceeding $7,500,000.

26

The Credit Agreement is guaranteed by all of BioReference’s domestic subsidiaries and is also secured by substantially all assets of BioReference and its domestic subsidiaries, as well as a non-recourse pledge by us of our equity interest in BioReference. Availability under the Credit Agreement is based on a borrowing base composed of eligible accounts receivables of BioReference and certain of its subsidiaries, as specified therein. As of March 31, 2024, $10.7 million remained available for borrowing under the Credit Agreement. Principal under the Credit Agreement is due upon maturity on August 30, 2025.

At BioReference’s option, borrowings under the Credit Agreement (other than swingline loans) bear interest at (i) the CB floating rate (defined as the higher of (x) the prime rate and (y) the SOFR Rate for an interest period ofonemonth plus2.50% and a benchmark spread adjustment of0.10%) plus an applicable margin of1.00%;or (ii) the SOFR Rate plus a benchmark spread adjustment of0.10% and an applicable margin of2.00%. Swingline loans will bear interest at the CB floating rate plus the applicable margin. The Credit Agreement also calls for other customary fees and charges, including an unused commitment fee of0.400% if the average quarterly availability is50%or more of the revolving commitment, or0.275% if the average quarterly availability is less than or equal to50%of the revolving commitments.

As of March 31, 2024 and December 31, 2023,$11.7 million and $12.7 million, respectively, was outstanding under the Credit Agreement.

The Credit Agreement contains customary covenants and restrictions, including, without limitation, covenants that require BioReference and its subsidiaries to maintain a minimum fixed charge coverage ratio if availability under the new credit facility falls below a specified amount and to comply with laws and restrictions on the ability of BioReference and its subsidiaries to incur additional indebtedness or to pay dividends and make certain other distributions to the Company, subject to certain exceptions as specified therein. Failure to comply with these covenants would constitute an event of default under the Credit Agreement, notwithstanding the ability of BioReference to meet its debt service obligations. The Credit Agreement also includes various customary remedies for the lenders following an event of default, including the acceleration of repayment of outstanding amounts under the Credit Agreement and execution upon the collateral securing obligations under the Credit Agreement. Substantially all the assets of BioReference and its subsidiaries are restricted from sale, transfer, lease, disposal or distributions to the Company, subject to certain exceptions. As of March 31, 2024, BioReference and its subsidiaries had net assets of approximately $456.0 million, which included goodwill of $217.7 million and intangible assets of $125.6 million.

In addition to the Credit Agreement, we had line of credit agreements with twelve other financial institutions as of March 31, 2024, and December 31, 2023, in the U.S., Chile and Spain. These lines of credit are used primarily as sources of working capital for inventory purchases.

The following table summarizes the amounts outstanding under the BioReference, Chilean and Spanish lines of credit:

(Dollars in thousands)

Balance Outstanding

Interest rate on borrowings at

Credit line

March 31,

December 31,

Lender

March 31, 2024

capacity

2024

2023

JPMorgan Chase

9.50 % $ 50,000 $ 11,668 $ 12,671

Itau Bank

5.50 %